Innate Pharma Ratios and Metrics

Market cap in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Feb '26 Feb 18, 2026	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020
Market Capitalization	160	166	233	282	400	334
Market Cap Growth	-5.83%	-29.08%	-17.19%	-29.50%	19.60%	-36.34%
Enterprise Value	121	107	180	196	283	177
Last Close Price	1.69	1.84	2.80	3.73	4.56	4.09
PS Ratio	10.77	7.95	3.43	4.58	14.24	3.92
PB Ratio	26.45	18.11	4.07	4.87	3.27	1.75
P/TBV Ratio	26.45	18.11	4.10	5.02	5.56	2.49
EV/Sales Ratio	8.14	5.15	2.65	3.19	10.07	2.07
EV/EBITDA Ratio	-	-	-	-	-	10.86
EV/EBIT Ratio	-	-	-	-	-	133.87
Debt / Equity Ratio	5.25	3.51	0.77	0.78	0.41	0.12
Debt / EBITDA Ratio	-	-	-	-	-	1.33
Net Debt / Equity Ratio	-6.41	-5.63	-1.01	-1.09	-0.70	-0.85
Net Debt / EBITDA Ratio	0.66	0.99	6.16	4.93	1.75	-9.96
Net Debt / FCF Ratio	0.80	6.83	1.60	3.01	1.27	2.52
Asset Turnover	0.10	0.14	0.33	0.25	0.09	0.20
Quick Ratio	2.08	2.50	3.51	3.21	1.67	3.64
Current Ratio	2.21	2.60	3.73	3.38	1.73	3.81
Return on Equity (ROE)	-271.37%	-162.91%	-14.28%	-71.75%	-34.53%	-0.44%
Return on Assets (ROA)	-25.92%	-22.52%	-4.23%	-4.40%	-10.40%	0.19%
Return on Invested Capital (ROIC)	-	-	-	-122.70%	-173.03%	5.30%
Return on Capital Employed (ROCE)	-79.80%	-66.10%	-9.30%	-10.40%	-25.50%	0.40%
Earnings Yield	-33.84%	-30.93%	-3.58%	-22.02%	-15.02%	-23.41%
FCF Yield	-30.51%	-4.56%	-15.58%	-7.46%	-16.89%	-19.27%
Buyback Yield / Dilution	-4.15%	-0.74%	-1.02%	-0.12%	-0.77%	-17.97%

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q